Predictive Oncology INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Axe Compute Inc. reported a significant increase in revenue for Q2 2026, driven by its Compute Services segment, but also disclosed substantial net losses and increased operating expenses.
Axe Compute reports Q1 2026 financial results, highlighting a strategic pivot to GPU compute services and a $260 million enterprise infrastructure contract.
Predictive Oncology Inc. reported a significant net loss of $82.17 million for the nine months ended September 30, 2025, driven by a $74.37 million derivative liability related to its new Aethir token (ATH) treasury strategy, while securing $50.8 million in cash and $173.3 million in ATH through private placements post-period.
Predictive Oncology Inc. reports continued significant losses, faces Nasdaq delisting, and is pursuing multiple capital raises and a reverse stock split to maintain operations and listing.
Predictive Oncology's Q1 2025 results reveal increased revenue driven by 3D model sales, alongside ongoing efforts to address financial uncertainties and the termination of a proposed merger with Renovaro.
Predictive Oncology's Q3 2024 results reflect a strategic shift with the discontinuation of its Birmingham operations, impacting revenue and profitability.
Predictive Oncology's Q2 2024 results show a decrease in revenue and a net loss, alongside the announcement of a strategic cost savings initiative.
Predictive Oncology's Q1 2024 results show increased revenue driven by STREAMWAY system sales, but the company continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.